阿维鲁单抗治疗侵袭性变异型或神经内分泌前列腺癌男性的2期试验
这项开放标签单中心2期试验纳入15例进展性神经内分泌或侵袭性变异型转移性前列腺癌(NEPC/AVPC)男性,给予阿维鲁单抗10 mg/kg每2周直至进展或不耐受。主要终点总缓解率(ORR)为6.7%,中位影像学无进展生存期1.8个月,中位总生存期7.4个月。研究因COVID-19疫情下入组缓慢而提前终止,阿维鲁单抗单药在微卫星稳定NEPC/AVPC中疗效不佳。
要点
- 阿维鲁单抗单药在微卫星稳定NEPC/AVPC中ORR为6.7%,中位rPFS 1.8个月,中位OS 7.4个月。
- 1例完全缓解患者携带MSH2体细胞突变、MSI-high且伴中枢神经系统转移,缓解持续2年。
- 外周免疫表型分析提示该异常缓解者存在CXCR2依赖的髓系和T细胞反应增强。
核心结论
- 尽管研究因COVID-19疫情初期入组缓慢和低于预期的客观缓解率而提前终止,阿维鲁单抗单药PD-L1抑制在微卫星稳定NEPC/AVPC患者中显示疗效不佳。
- 免疫分析显示唯一异常缓解者存在CXCR2阳性免疫细胞活化增强,提示该人群免疫治疗进一步开发的潜在机制。
研究设计与样本
- 开放标签单中心2期试验(NCT03179410),纳入经组织学或AVPC标准定义的进展性NEPC/AVPC男性。
- 阿维鲁单抗10 mg/kg每2周给药直至进展或不可接受毒性。
- 主要终点为总缓解率(ORR),次要终点包括ORR、影像学无进展生存期(rPFS)、总生存期和安全性,相关研究包括纵向外周血免疫表型分析。
- 共入组15例男性,中位年龄71岁(范围51-85岁),既往接受中位2线治疗(范围1-3),中位PSA 54 ng/dl(范围0-393),73%有肝转移。
主要发现
- 按iRECIST或RECIST 1.1评估,阿维鲁单抗的ORR为6.7%,包括1例(6.7%)完全缓解(CR)、20%疾病稳定和67%疾病进展。
- CR患者有MSH2体细胞突变和MSI-high NEPC伴中枢神经系统转移,其CR在停止所有治疗后仍持久达2年。
- 中位rPFS为1.8个月(95% CI 1.6-3.6个月),中位总生存期为7.4个月(85% CI 2.8-12.6个月)。
- 安全性特征与阿维鲁单抗已知特征一致。
- 外周免疫亚群表型分析提示该异常缓解者存在CXCR2依赖的髓系和T细胞反应增强。
临床怎么用
- 原文结论为阿维鲁单抗单药在微卫星稳定NEPC/AVPC患者中显示疗效不佳,未据此给出推荐。
局限性
- 研究受限于入组患者数量少。
- 研究因COVID-19疫情而提前终止。
- 研究因COVID-19疫情初期入组缓慢而提前终止。
- 客观缓解率低于预期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. METHODS: We conducted an open label single center phase 2 trial (NCT03179410) of men with progressive NEPC/AVPC either defined by histology or AVPC criteria. Avelumab (10 mg/kg every 2 weeks) was administered until progression or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Secondary endpoints included ORR, radiographic progression-free survival (rPFS), overall survival, and safety. Correlative studies included longitudinal peripheral blood immune phenotyping. The study was limited by the small number of patients enrolled and by the early termination due to COVID-19. RESULTS: A total of 15 men with AVPC/NEPC were enrolled. The median age was 71 (range 51-85 years), and men had received a median of two prior therapies (range 1-3). Median PSA was 54 ng/dl (range 0-393), and 73% of men had liver metastasis. The ORR with avelumab in this setting by iRECIST or RECIST 1.1 was 6.7%, including one patient (6.7%) with a complete remission (CR), 20% with stable disease, and 67% with progressive disease. The patient with the CR had an MSH2 somatic mutation and MSI-high NEPC with central nervous system metastases, and his CR remains durable off all therapy for 2 years. The median rPFS was 1.8 months (95% CI 1.6-3.6 months), and median overall survival was 7.4 months (85% CI 2.8-12.6 months). Safety was consistent with the known profile of avelumab. Phenotyping of peripheral immune subsets suggest enhanced CXCR2-dependent myeloid and T-cell responses in this extraordinary responder. CONCLUSIONS: While the study was terminated early due to slow enrollment at the onset of the COVID-19 pandemic and lower than anticipated objective response rate, PD-L1 inhibition with avelumab monotherapy showed poor efficacy in patients with microsatellite stable NEPC/AVPC. Immune profiling revealed enhanced CXCR2 positive immune cell activation in the one extraordinary responder, suggesting potential mechanisms for further immunotherapy development in this population.
引用
- Brown LC, Halabi S, Somarelli JA, et al. A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer. Prostate Cancer Prostatic Dis. 2022. PMID: 35292724. doi:10.1038/s41391-022-00524-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。